J Biol Chem, Vol. 274, Issue 36, 25883-25891, September 3, 1999
Purification and Analysis of Authentic CLIP-170 and
Recombinant Fragments*
Jochen
Scheelabc,
Philippe
Pierreacd,
Janet E.
Rickardace,
Georgios S.
Diamantopoulosa,
Caterina
Valettiaf,
F. Gisou
van der Gootg,
Markus
Hänerh,
Ueli
Aebih, and
Thomas E.
Kreisai
From the a Department of Cell Biology, Sciences III, and
g Department of Biochemistry, Sciences II, University of Geneva,
CH-1211 Geneva 4 and h Biozentrum, M. E. Müller
Institute for Structural Biology, University of Basel,
CH-4056 Basel, Switzerland
 |
ABSTRACT |
We have purified authentic CLIP-170
(cytoplasmic linker protein of
170 kDa) and fragments comprising functional domains of the
protein to characterize the structural basis of the function of
CLIP-170. Analysis of authentic CLIP-170 and the recombinant fragments
by electron microscopy after glycerol spraying/low angle rotary metal
shadowing reveals CLIP-170 as a thin, 135-nm-long molecule with two
kinks in its central rod domain, which are approximately equally spaced
from the two ends of the protein. The central domain consisting of
heptad repeats, which is
-helical in nature and forms a 2-stranded
coiled-coil, mediates dimerization of CLIP-170. The rod domain harbors
two kinks, each spaced ~37 nm from the corresponding end of the
molecule, thus providing mechanical flexibility to the highly elongated
molecule. The N-terminal domain of CLIP-170 binds to microtubules
in vitro with a stoichiometry of one dimeric head domain
per four tubulin heterodimers. Authentic CLIP-170 binds to microtubules
with lower stoichiometry, indicating that the rod and tail domains
affect microtubule binding of CLIP-170. These results document that
CLIP-170 is a highly elongated polar molecule with the
microtubule-binding domain and the organelle-interacting domains at
opposite ends of the homodimer, thus providing a structural basis for
the function of CLIP-170 as a microtubule-organelle linker protein.
 |
INTRODUCTION |
Correct intracellular membrane traffic and the cytoarchitecture of
eukaryotic cells depends on cytoplasmic microtubules. The dynamic
properties intrinsic to tubulin assembly could also be regulated by
interactions of cell organelles with microtubules (1). These
interactions are mediated by
MBPs1 (reviewed in Ref. 2),
as well as being dependent on force-generating proteins (reviewed in
Ref. 3). Accessory proteins in addition to motor proteins like kinesins
or dyneins are required to regulate and specify organelle-microtubule
interactions (4, 5). CLIP-170 (6) is a non-motor MBP originally
identified in HeLa cells (7), which localizes preferentially to
elongating microtubule plus ends (8, 9) and is proposed to mediate
interactions of endocytotic organelles (10) and chromosomes (11) with
microtubules. The primary structure of CLIP-170 predicts a protein that
is elongated, with two functional domains separated by a 950-amino acid
stretch of heptad repeats. The N-terminal domain has two conserved
motifs shown to mediate binding of the protein to microtubules (10). The C-terminal domain, on the other hand, is predicted to interact with
other organelles and has been shown to mediate targeting of CLIP-170 to
prometaphase kinetochores (11). The C-terminal domain, which contains
two predicted metal-binding motifs, and the N-terminal
microtubule-binding domains are highly conserved in vertebrate CLIP-170
homologues (10, 12) and in the putative Drosophila
melanogaster CLIP-170 homologue, D-CLIP-190 (13), suggesting they
play an important functional role.
The microtubule-binding domain of CLIP-170 (10) shows similarities to
dp150glued (14, 15), a subunit of the dynactin complex, which
is involved in regulating cytoplasmic dynein activity (reviewed in Ref.
4). In contrast to dp150glued, however, CLIP-170 is not part of
a protein complex. Bik1p, which is required for microtubule-related
functions during mitosis in yeast, also contains a microtubule-binding
domain similar to CLIP-170 (16), as do two proteins implicated in
correct folding of
- and
-tubulin (17, 18). This motif,
therefore, appears in several proteins with distinct roles in
microtubule function (reviewed in Ref. 6). One of the C-terminal
metal-binding motifs is also found in the yeast protein Bik1p (16).
Dp150glued and Bikp have an additional similarity to CLIP-170
in that they contain predicted heptad repeats that should allow
dimerization, although this has not been established experimentally.
Thus, the sequence of CLIP-170 predicts three major domains, each of
which shows homology with domains in related proteins and are predicted to play specific functional roles.
Further analysis of the structure and activity of CLIP-170 is necessary
to understand its in vivo function. For this purpose, highly
purified protein as well as fragments comprising functional domains are
required. We have developed a protocol for purification of authentic
CLIP-170 from human placenta based on immunoaffinity chromatography
(19), and we have also used the cDNA from HeLa cells (10) to
express and purify predicted functional domains of the protein. A
combination of biochemical, biophysical, and electron microscopy
analyses reveals CLIP-170 as a highly elongated homodimer, with
microtubule-binding and organelle-interacting domains separated by an
-helical 2-stranded coiled-coil domain. This rod domain, which
contains two prominent kinks, and the C-terminal tail appear to
negatively influence the binding of CLIP-170 to microtubules. These
results provide a structural basis for the function of CLIP-170 as a
microtubule-organelle linker protein.
 |
EXPERIMENTAL PROCEDURES |
Purification of CLIP-170--
CLIP-170 was purified from human
placenta by immunoaffinity chromatography and microtubule affinity as
described (20). Proteins copurifying with CLIP-170 were not detected
even when the 1 M salt wash step of the affinity column was
omitted. CLIP-170 eluted from microtubules by high salt was either
dialyzed against NMEG (50 mM NH4OAc, 0.1 mM MgSO4, 0.5 mM EGTA, 20%
glycerol, pH 6.9) or further purified by gel filtration chromatography
using a Superose 12 column (Superose 12 HR 10/30; Amersham Pharmacia
Biotech). 0.3-ml samples were loaded and separated at 0.5 ml/min in PEM (0.1 M KPIPES, 2 mM EGTA, 1 mM
MgSO4, pH 6.8) or NMEG. Fractions of 0.2 ml were collected
and analyzed by UV spectrophotometry and SDS-PAGE. Fractions containing
pure CLIP-170 with more than 0.1 mg/ml protein were pooled and either
analyzed directly or frozen in liquid nitrogen and stored at
80 °C.
Generation of Recombinant CLIP-170 Fragments--
An
NdeI restriction site was introduced at the first ATG codon
of the CLIP-170 cDNA in pBS KS by PCR mutagenesis to obtain plasmid
pCLIP.NdeI (21). The head fragments were generated by first
inserting an NdeI-XhoI fragment from this plasmid
into pET19b (Novagen, AMS, Lugano, Switzerland), which allows
expression with an N-terminal stretch of histidines, and then deleting
parts of the rod and tail by digestions with EspI (H2) and
religation, or with KpnI/EspI (H1) or
SphI/BamHI (H3), blunting of the ends, and
religation. All positions given are for the cDNA according to
Pierre et al. (10). T1 was introduced in pET19b after
digestion of the pCLIP.NdeI plasmid using a first
XhoI (nucleotide 3860) site in the region coding for the
C-terminal part of CLIP-170 and a second site in the vector. Tail
domains (T2, T3, T4, T5, and T6) were amplified by the PCR on plasmid
pM1CLIP-170 (10) using appropriate forward primers containing an
NdeI site and a second primer in the 3'-nontranslated region
of CLIP-170 cDNA incorporating an EcoRV site. PCR
products were digested with NdeI and EcoRV and
cloned into pET19b which had been digested with NdeI at the
3' end and BamHI followed by blunting with T4 polymerase at
the 5' end. The rod domain was introduced in pET19b following a similar
PCR-based strategy using an NdeI site at the 5' end and the
XhoI site (position 3864) to eliminate the C-terminal domain
of CLIP-170. The following primers were used: forward primers, R
(primer position 1392) 5'-GCGACATATGGTGGAAGCTGCTGA-3'; T6 (2184) 5'-TAAACATATGGAAGCCTTGAGGGCT-3'; T5 (2630)
5'-AGACATATGCAAGAAACTGTAAAT-3'; T4 (3054)
5'-AAGCATATGGAAACAAGCCACAAC-3'; T3 (3320)
5'-AAGCATATGACTCTGGCCTCCTTGGAG-3'; T2 (3557)
5'-AAACATATGGAGGAGCTGGGGAGA-3'; reverse primer (4300) 5'-CGTCTGAGCAAGCCCAGT-3'.
All constructs were expressed in Escherichia coli
strain BL21(DE3)pLysS except for T1 which was expressed in
HMS174(DE3)pLysS (Novagen) by growth of well-aerated cultures at
37 °C to OD <0.5, induction of protein expression by addition of 1 mM isopropyl
-D-thiogalactopyranoside, and
further incubation for 2.5 h at 37 °C. Bacteria were harvested
by centrifugation, washed in 0.2 volumes of 40 mM Tris-HCl,
10 mM imidazole, pH 8.0, resuspended in 0.05 volumes of the
same buffer, and snap-frozen in liquid nitrogen. After freezing, the
cells were left at least 5 min in liquid nitrogen or, more usually,
overnight at
80 °C before thawing quickly in a 37 °C water
bath. The thawed lysate was incubated with 25 µg/ml DNase I, 5 mM MgCl2, and 0.2% Triton X-100 for 5-30 min
at 0 °C until no longer viscous. After addition of one sample volume
of 1 M NaCl, the lysate was cleared by centrifugation at 25,000 × g for 20 min at 4 °C. Cleared lysates were
used directly for immunoblotting or recombinant proteins were purified
by metal chelate chromatography. For all constructs except T1, 1-ml
columns of His-bindTM resin (Novagen) charged with Ni2+
were equilibrated with 5 mM imidazole, 0.5 M
NaCl, 20 mM Tris-HCl, pH 7.9, before loading cleared
lysates derived from up to 250 ml of bacterial culture. Columns were
washed with 5 column volumes of 60 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9, before elution
of bound proteins by 1 M imidazole, 0.5 M NaCl,
20 mM Tris-HCl, pH 7.9. For the T1 construct, protein
purified by this method was found to be aggregated, so it was purified
using nickel-nitrilotriacetic acid resin (Diagen GmbH,
Düsseldorf, Germany) which allowed the use of reducing agent. The
protocol was as above except that 10 mM 2-mercaptoethanol
was included in the washing/freezing buffer and all the column buffers
and 1 mM dithiothreitol was included in buffers for
dialysis and individual experiments. Fractions of 0.5 ml were collected
from the columns, and protein-containing fractions were pooled.
Proteins were dialyzed into the buffers described for individual
experiments and either used directly or snap-frozen in liquid nitrogen
and stored at
80 °C.
Epitope Mapping and Immunoblotting--
Proteins from cleared
lysates of isopropyl
-D-thiogalactopyranoside-induced
clones harboring expression constructs of CLIP-170 were analyzed by
immunoblotting as described (7) using monoclonal (19) and polyclonal
(10) antibodies against CLIP-170. None of the mAbs 2D6, 3A3, and 4D3
bound to H fragments. mAb 2D6 bound to all the tail fragments including
T1 but not to R, which places the epitope of mAb 2D6 beyond amino acid
1237. mAbs 3A3 and 4D3 bound to fragments T4, T5, and T6 and to R, but
not to fragments T3, T2, or T1, which places the epitope of these two
monoclonal antibodies between amino acids 971 and 1059. The polyclonal
anti-55 antibody (10) bound fragments H2, H3, and R, but not H1; the main epitope of this antibody thus appears to be confined to the sequence between amino acid 350 and 854. The localization of these antibody epitopes is summarized in Fig. 4. The ability of 4D3 to bind
to the rod domain but not the C-terminal domain allows the effect of
cellular overexpression of the tail domain on localization of the
endogenous protein to be studied (11).
Circular Dichroism and Amino Acid Analysis--
Circular
dichroic experiments were performed at room temperature using a Jasco
600 autodichrograph spectrometer and quartz cells of 0.1-mm path
length. The protein concentration of the purified R fragment was 1.28 µM as determined by amino acid analysis in
phosphate-buffered saline. Protein samples were hydrolyzed in 6 M HCl at 110 °C for 24 h in vacuo and
subjected to amino acid analysis. The
-helical content was estimated
either as described by Bruch et al. (22) or using the CONTIN
program (23).
Physical Characterization of Recombinantly Expressed CLIP-170
Fragments--
The sedimentation coefficient of the purified
recombinant proteins was measured by sucrose gradient centrifugation as
described before (10). Bacterially expressed proteins purified as
described above were dialyzed against PEM, and 0.2-ml samples were
loaded onto 4-ml sucrose gradients (5-20% in PEM) and spun at 38,000 rpm for 22 h at 4 °C in a TST 60.4 rotor (Kontron, Zurich,
Switzerland). Standard proteins and their sedimentation coefficients
(s20,w × 1013 S) were
bovine heart cytochrome c (1.71), bovine serum albumin (4.41), yeast alcohol dehydrogenase (7.40), and sweet potato
-amylase (8.98). Fractions of 0.2 ml were collected from the top of
the gradient and analyzed for protein content by a protein assay (24) for the standard proteins and by SDS-PAGE for the recombinant proteins,
to locate the peak of undegraded protein; the sucrose concentration was
established using a Bausch & Lomb refractometer. The diffusion
coefficient, D20,w, was measured by gel filtration chromatography on Sephacryl beads. S-300, S-400, and S-500
HR beads (Amersham Pharmacia Biotech) packed in columns of 10-mm
diameter by 450-mm length (~35 ml total volume) were equilibrated in
PEM buffer and run at 0.3 ml/min. Samples of 0.2 ml in PEM were loaded,
and 0.6-ml fractions were collected and analyzed by protein assay for
standard proteins and by SDS-PAGE for the recombinant proteins. In some
cases, the bacterial lysate was analyzed and the protein located by
immunoblotting. No significant difference was found between crude and
purified proteins. Standard proteins and their diffusion coefficients
(×107 cm2/s) were bovine heart cytochrome
c (11.40), chymotrypsinogen A (9.50), chicken ovalbumin
(7.03), bovine serum albumin (6.90), sweet potato
-amylase (5.77),
bovine
-globulin (4.10), bovine liver catalase (4.10), horse spleen
apoferritin (3.61), bovine thyroglobulin (2.52), and human fibrinogen
(1.98). The Vt was measured using the dipeptide
Tyr-Gly, and V0 was measured with blue dextran.
Not all proteins were resolved on each column; only values that fell on
the linear part of a 1/D versus
Kav plot were used, and at least five standard
proteins were used to calibrate each column. All standard proteins were
purchased from Sigma. The native molecular weight, Stokes radius, axial
ratio, and approximate physical dimensions were calculated according to
Bloom et al. (25).
Analysis of Microtubule Binding--
Microtubule binding was
assayed as described (10). Briefly, CLIP-170, H1, or H2 were diluted
into 50 µl of PEM plus 20 µM paclitaxel and incubated
with or without 5 µg of paclitaxel-stabilized microtubules at
37 °C for 15 min, before sedimentation through a 100-µl cushion of
10% sucrose in PEM at 30,000 × g for 30 min at
20 °C. The pellet was dissolved in gel loading buffer, and equivalent volumes of the supernatant and pellet samples were separated
by 8% SDS-PAGE and staining with Coomassie Blue. For quantitation of
proteins in the pellets, serial dilutions of the pellet samples were
separated by SDS-PAGE; the Coomassie Blue-stained gels were scanned
with an Agfa Arcus II Desktop scanner, and the bands were quantitated
using ScanAnalysis version 2.50 software.
Electron Microscopy--
Purified protein was equilibrated,
either by adding concentrated stock solutions or by dialysis (twice for
1 h against 200 volumes at 4 °C), against NMEG. Once in this
buffer, the protein samples were either kept on ice for 1 day or
snap-frozen in liquid nitrogen and kept at
80 °C. Immediately
before spraying the samples onto a piece of freshly cleaved mica, more
glycerol was added to a final concentration of 30%. Sprayed samples
were dried in an evaporator then rotary shadowed at a low elevation
angle (3-5°) with platinum/carbon as described (26, 27).
Micrographs were recorded on a Hitachi H-8000 transmission electron
microscope (Hitachi Ltd., Tokyo, Japan) operated at 100 kV. For
preparing figures, micrographs were digitized with a Leafscan 45 flat-bed scanner (Leaf Systems Inc., Westbourough, MA) at a step size
of 2450 dpi. The digitized micrographs were processed using Adobe
Photoshop (version 5.0) software (Adobe Systems Inc., Mountain View,
CA) and printed so that piled up metal (representing molecules)
appeared bright on prints. Length measurements of the molecules were
performed by computerized tracking on 2.5-fold magnified electron
micrographs. The thus-gathered lengths data were presented as
histograms that were fitted by Guassian curves employing the
custom-designed IMPSYS program package (28).
 |
RESULTS |
Purification and Characterization of Authentic CLIP-170 from Human
Placenta--
CLIP-170 has previously been isolated from HeLa cells by
antibody affinity purification (19). However, the protein obtained was
not homogeneous, and the yield was too low to make further purification
practical. In order to obtain pure preparations of CLIP-170 in
sufficient quantities for further characterization, it was purified to
homogeneity from human placenta. Greater quantities of protein might
also be obtained by bacterial expression of recombinant CLIP-170, but
the complete protein was found to be rapidly degraded in bacteria.
However, we expressed and purified recombinant fragments of CLIP-170,
which allows characterization of individual functional domains of the
protein and comparison of their properties with authentic CLIP-170.
The purification scheme of authentic CLIP-170 from human placenta
(Table I) involves affinity
chromatography using a mAb against CLIP-170 (19) followed by
microtubule affinity purification and gel filtration and is described
in detail elsewhere (20). Affinity chromatography using mAb 3A3, the
species specificity of which dictated the use of human tissue, was the
most effective single purification step, resulting in 5,800-fold
enrichment of CLIP-170. The protein is further purified by binding to
microtubules, which removes all contaminating proteins to enrich a
further 6-7-fold. A final gel filtration step, to remove traces of
tubulin introduced in the microtubule-binding step, can be omitted for
most biochemical and EM analyses. The entire purification scheme yields
a 42,000-fold enrichment of CLIP-170 with a yield of 0.2 mg of pure
CLIP-170 per 500 g of placenta (Table I). The final product
appears homogeneous after gel electrophoresis and silver staining (Fig.
1). By using purified protein as a
standard, it was estimated that CLIP-170 represents 0.002% of total
placenta high speed supernatant protein.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 1.
SDS-PAGE analysis of CLIP-170 purification
from human placenta. Samples of the high speed supernatant
(lane 1), the eluate of the immunoaffinity column
(lane 2), the microtubule eluate (lane 3), and
the peak fractions eluted from the gel filtration column (lane
4) during the preparation of CLIP-170 were analyzed by 10%
SDS-PAGE followed by silver staining. Molecular weights
(×10 3) are shown on the left.
|
|
In order to validate the use of purified CLIP-170 from human placenta
for structural studies, we characterized the purified protein and
compared it to CLIP-170 from HeLa cells (7, 10, 19). CLIP-170 from HeLa
cells and human placenta behave very similarly by SDS-PAGE (see below)
or gel filtration chromatography (data not shown), are identical in
their reactivity for eight different polyclonal antibodies (seven
anti-peptide antibodies and anti-55; Ref. 10) and three different mAbs
(2D6, 3A3, 4D3; Ref. 19), and by their behavior during gel filtration
chromatography (data not shown). One peptide antibody, anti-KMRL
(raised against a peptide according to CLIP-170 amino acids 619-638;
see Pierre et al. (10)), however, binds to CLIP-170 from
HeLa cells but not from human placenta (Fig.
2). This suggests that CLIP-170 from
human placenta differs from HeLa CLIP-170 in a small region of the
coiled-coil domain. This difference might arise by alternative splicing, similar to what is observed in another CLIP-170 isoform, restin (12, 29).

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 2.
Comparison of HeLa and placenta CLIP-170 by
SDS-PAGE and immunoblotting with two anti-peptide antibodies.
CLIP-170 purified by antibody affinity column from HeLa cells
(lanes 1, 3 and 5) or human placenta (lanes
2, 4 and 6) was separated by 7% SDS-PAGE, and the gels
were stained with Coomassie Blue (lanes 1 and 2)
or immunoblotted with anti-KRKV (lanes 3 and 4)
or anti-KMRL (lanes 5 and 6) anti-peptide
antibodies. Numbers at the left indicate the
position of molecular weight markers (×10 3). CLIP-170
from HeLa cells or placenta have a very similar electrophoretic
mobility, but of the two anti-peptide antibodies used here, both raised
against sequences of the HeLa protein, only one reacts with the protein
from placenta, indicating some sequence difference between the proteins
from the two sources. Note that the anti-KRKV reactivity shows that
slightly more placenta CLIP-170 that HeLa CLIP-170 was loaded on the
gel, which means that the lack of reaction with the anti-KMRL antibody
is not a problem of detection limit.
|
|
Proteins co-purifying with CLIP-170 were not detected with the
purification scheme used (Fig. 1, lane 4), although binding of CLIP-170 to mAb 3A3 or to microtubules occurred under mild conditions and physiological pH and salt concentrations. Thus, the
majority of CLIP-170 appears not to be part of a protein complex or
strongly bound to interacting partners, as was previously observed for
the protein isolated from HeLa cells. The purification procedure does
not significantly alter the shape of CLIP-170, since the purified
protein has the same hydrodynamic properties as the protein in the
crude lysate (data not shown). The purified protein was also tested for
its ability to bind to paclitaxel-stabilized microtubules. At low
concentrations of CLIP-170, most of the protein sediments with the
microtubules, but very little sediments in the absence of microtubules
(Fig. 3A, cf. lanes
2 and 4). With two different CLIP-170
preparations, it appeared that up to 10% of the protein may be unable
to bind to microtubules. This was surprising since it was purified by
microtubule affinity; in both cases the protein had been stored frozen
before analysis, which may mean there is some loss of activity on
freezing. At higher concentrations of CLIP-170, a greater proportion
remains in the supernatant, showing that the binding to microtubules is
saturable (Fig. 3A, lanes 5 and 6).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3.
Analysis of the microtubule-binding activity
of placenta CLIP-170 and the bacterial proteins H1 and H2.
A, purified human CLIP-170 at ~20 (lanes 1-4)
or ~120 µg/ml (lanes 5 and 6); B,
bacterially expressed H1 fragment of CLIP-170 at 50 (lanes
1-4) or 150 µg/ml (lanes 5 and 6); and
C, H2 fragment of CLIP-170 at 50 (lanes 1-4) or
150 µg/ml (lanes 5 and 6) were incubated
without (lanes 1 and 2) or with (lanes
3-6) paclitaxel microtubules before centrifugation, and
supernatants (lanes 1, 3, and 5) and pellets
(lanes 2, 4, and 6) were analyzed by 8% SDS-PAGE
and staining with Coomassie Blue. Numbers at the
left indicate the position of molecular weight markers
(×10 3), and arrows on the right
mark the position of CLIP-170, H2, and H1. The structure of H1 and H2
is indicated in Fig. 4. In the absence of microtubules, very little of
each protein sediments; there is a higher level of nonspecific
pelleting of CLIP-170, most likely due to nonspecific sticking to the
tubes. For each protein, the incubation at lower concentration
demonstrates that the proteins are fully active for microtubule
binding, whereas at higher concentrations a significant proportion
remains in the supernatant, showing that the binding is
saturable.
|
|
Purification and Characterization of Fragments of CLIP-170
Expressed in Bacteria--
Previous analysis of the sequence of the
cDNA encoding CLIP-170 in HeLa cells predicted three functional
domains as follows: an N-terminal 350-amino acid domain, which has been
shown to bind to microtubules; a C-terminal 80-amino acid domain, which
contains two metal-binding motifs; and a central 960-amino acid domain of heptad repeats (10). To analyze the biochemical and biophysical properties of individual domains of CLIP-170 and to study their structural properties in relation to the authentic protein, various fragments of the protein were expressed from the HeLa cDNA in E. coli (summarized in Table
II). One series of fragments contains the
N-terminal head domain of CLIP-170 with various numbers of heptad
repeats from the rod domain (H fragments), another series of fragments
contains various numbers of heptad repeats from the rod and the
C-terminal tail domain (T fragments), and one fragment (R) consists
entirely of the heptad repeats of the central rod domain (Fig.
4A). The proteins were
expressed with N-terminal histidine tags and purified for analysis. All
the expressed fragments had the expected size as determined by gel
electrophoresis (Fig. 4B) and immunoblotting with
anti-peptide antibodies (data not shown).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Expression of CLIP-170 fragments as fusion
proteins in bacteria. A, the primary structure of
fragments of CLIP-170 expressed in bacteria is schematized and compared
with that of CLIP-170 (wild type, WT). The name of each
protein and the predicted molecular weight of the polypeptide
(×10 3) is indicated on the right. At the
bottom is indicated the regions containing the epitopes
recognized by four antibodies against CLIP-170. B, the
recombinant fragments of CLIP-170 expressed in bacteria and purified
were separated on 12% SDS gels and stained with Coomassie Blue. Names
of the proteins are those given in A, and numbers
at the right indicate the position of molecular weight
markers (×10 3).
|
|
The shape and state of oligomerization of CLIP-170 fragments were
determined by calculating their native molecular weights and
dimensions, based on measurements of diffusion coefficients and
sedimentation coefficients of the recombinant fragments. This analysis
indicates that all are elongated molecules with widths of less than 5 nm (summarized in Table III). Calculation
of the native molecular weight of the fragments shows that proteins
that do not contain heptad repeats of the rod domain (H1) are
monomeric, whereas proteins that contain heptad repeats (H2, 18 heptads) are dimeric. All of the expressed T constructs are also
dimeric, including T1 that contains only 10 heptad repeats. This
suggests that both the beginning and end of the coiled-coil domain have a strong tendency to associate to form dimeric structures. All of the
dimeric H and T constructs are much longer than predicted for their
coiled-coil regions (30), suggesting that both the N- and C-terminal
domains of CLIP-170 are rather elongated. The N-terminal domain appears
to be 35-50 nm long, and the C terminus ~15 nm long. This is
confirmed for the N-terminal domain by measurement of the monomeric H1,
which has a measured length of 35 nm (Table III). The central domain,
which consists entirely of 116 heptad repeats, is a thin rod with
estimated dimensions of 116 × 2 nm. Circular dichroism
measurements, revealing characteristic minima at 208 and 222 nm (Fig.
5), confirm the
-helical nature of the rod domain. The percentage of
-helical content was estimated by two
different methods (22, 23) to be between 91 and 97%. The length of the
rod domain (116 nm) and its
-helical nature are in agreement with
the presence of 116 heptad repeats with a predicted length of ~1 nm
each in coiled-coils (30).

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 5.
Far ultraviolet circular dichroism spectrum
of the R fragment. Ellipticities are expressed per mol of peptide
bonds.
|
|
Previous work has shown that the N-terminal 350-amino acid fragment of
CLIP-170 (H1) contains the microtubule-binding domain (10). The
availability of highly purified authentic protein and fragments thereof
enables quantitative analysis of their microtubule-binding properties.
In addition, comparison of monomeric H1 with dimeric H2 and authentic
protein allows determination of the effect of dimerization of rod and
tail domains on microtubule binding. Both H1 and H2 did not sediment in
the absence of microtubules, were fully active in binding to
microtubules, and the binding was saturable (Fig. 3, B and
C). The stoichiometry of binding of CLIP-170, H1, and H2 to
microtubules was estimated by quantitative scanning of gels of the
pellet samples at saturation (Fig. 3, A-C, lane 6). Weight
ratios of tubulin to CLIP-170, H1, and H2 were 4.5:1, 4.4:1, and 3.9:1
respectively. By using molecular weights of 100,000 for tubulin (31),
306,000 for CLIP-170 (10), 40,000 for H1, and 110,000 for H2 (Table
III), these values give molar ratios of tubulin:protein of 13.8:1,
1.8:1 and 4.3:1, for CLIP-170, H1, and H2, respectively. Thus, the rod
domain or the C-terminal domain negatively influences the binding of
CLIP-170 to microtubules, which might be due to structural properties
of these domains.
EM Analysis of Authentic CLIP-170 and Recombinantly Expressed
Fragments--
EM after glycerol spraying/low angle rotary metal
shadowing of the samples was used to visualize directly the authentic
and recombinant proteins. Authentic CLIP-170 yielded long, often bent or kinked, rod-shaped particles (Fig.
6a). Frequently one or
sometimes both ends of these rod-shaped molecules were flanked by a
pair of small globular heads, which had some tendency to coalesce. However, the variability of the two end domains from one particle to
the next was such that no clear polarity of the CLIP-170 molecule became apparent. This morphological finding was somewhat surprising since the two end domains were expected to be rather asymmetric (i.e. the N-terminal end domain is 350 whereas the
C-terminal end domain is 80 amino acid residues long). Nevertheless, it
is likely that the N-terminal end domain of the purified protein is
folded correctly, since it binds to microtubules, an activity mediated
by the N-terminal end domain.

View larger version (176K):
[in this window]
[in a new window]
|
Fig. 6.
Electron microscopic analysis of human
CLIP-170 and recombinantly expressed CLIP-170 fragments. Selected
particle galleries of human CLIP-170 (a), of a C-terminally
truncated fragment H3 (b), and of N-terminally truncated
fragments T6 (c), T5 (d), and T3 (e)
after preparation of the samples by glycerol spraying/low angle rotary
metal shadowing. Bottom, length histograms measured from
authentic and recombinant CLIP-170 particles displayed in
(a e). Particle length in nanometers on the
abscissa is plotted against the number of particles on the
ordinate. The histograms were fitted by a single Gaussian
curve to give the mean length in nanometers (± S.D.). Scale
bar, 50 nm (a e).
|
|
The average length of the central rod domain of CLIP-170 seen by EM of
glycerol-sprayed/low angle rotary metal-shadowed samples was measured
to be 135 nm (Fig. 6), in good agreement with the predicted length of a
959-residue-long (residues 350-1308) two-stranded
-helical
coiled-coil (i.e. ~140 nm). This value is also consistent with the length previously calculated from biophysical properties of
CLIP-170 from HeLa cells (i.e. 110 nm) (10). Hence, the
overall size and shape of the full-length human CLIP-170 molecule as
determined by EM fits best with a rod-shaped homodimer with two
polypeptides being associated in register via their central
959-residue-long, heptad repeat-containing rod domain to form a
2-stranded
-helical coiled-coil.
The bacterially expressed fragments of CLIP-170 were also analyzed by
EM of glycerol-sprayed/rotary metal-shadowed samples. None of the three
C-terminal truncation constructs (H1, H2, and H3; see Table II)
appeared as rod-shaped particles (shown for H3 in Fig. 6b).
This is predicted for the H1 fragment, which lacks heptad repeats
(Table II) and stays monomeric according to biophysical measurements
(Table III). However, the finding is somewhat surprising for the H2 and
H3 constructs, which contain 18 and 30 heptad repeats, respectively
(see Table II), and, upon dimerization via 2-stranded
-helical
coiled-coil formation, should yield rod-shaped segments ~20 and >30
nm long, respectively. In contrast, the three C-terminal constructs
(T3, T5, and T6; see Table II) yielded rod-shaped particles (Fig. 6,
c-e) with average lengths (Fig. 6, length histograms) which
agree with the size predicted from their corresponding
-helical coiled-coil rod segments (Table II).
Since the EM images of both the authentic and N-terminally truncated
CLIP-170 frequently revealed one or two distinct kinks (Fig. 6,
a and c), we analyzed statistically the distances
of these kinks from the termini of the protein and from each other (Fig. 7). Whereas in the case of the
full-length authentic protein, due to the lack of evident polarity, the
assignment of their N- and C-terminal end was arbitrary, in the case of
the N-terminally truncated CLIP-170 fragments, T6 and T5, we could in
most cases morphologically determine their C-terminal ends. In the case
of full-length CLIP-170, the two kinks were rather symmetrically spaced
from the particle ends, for example 36 ± 10 nm from one end and
38 ± 11 nm from the other end (Fig. 7), with the two kinks being
spatially separated by 63 ± 12 nm. Analysis of the N-terminally truncated fragments T5 and T6 shows that the kink is 36 ± 4 or 37 ± 6 nm from the C terminus, respectively (Fig. 7). A
36-nm-long coiled-coil rod segment corresponds to ~34 heptad repeats
(30), i.e. 250 amino acids, and analysis of the CLIP-170
sequence by the PairCoil program suggests that the
coiled-coil domain covers residues 350-1300. The N-terminal kink
should, therefore, occur around amino acid residue 600 (350 + 250),
whereas the C-terminal kink should occur around amino acid residue 1050 (1300-250). Indeed, an interruption of the heptad-repeat pattern in
the primary sequence is predicted around residue 600 but not around
residue 1050.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
Analysis of the position of kinks in the rod
domain of CLIP-170. Statistical analysis of the positions of two
distinct kinks detected in the rod domain of CLIP-170 (wt)
and the N-terminally truncated fragments T6 and T5. A,
schematic representation of the molecules showing the particle segments
measured: a, distance of the N-terminal kink to the N
terminus; c, distance of the C-terminal kink to the C
terminus; b, distance between the two kinks; b'
and b", distance of the C-terminal kink to the N terminus of
T6 and T5, respectively. B, particle length in nanometers on
the abscissa is plotted against number of particles on the
ordinate. The histograms were fitted by a single Gaussian
curve to give the mean length in nanometers (± S.D.). Assignment of
the N and C termini of the full-length CLIP-170 molecule was
arbitrary.
|
|
 |
DISCUSSION |
CLIP-170 is a cytoplasmic linker protein proposed to mediate
transient interactions of organelles with microtubules (10, 11). We
have analyzed purified authentic CLIP-170 and bacterially expressed
fragments to elucidate the organization and structure of the functional
domains of the protein. EM analysis of glycerol-sprayed/rotary metal-shadowed protein revealed the elongated structure of CLIP-170, but the lack of difference in morphology between the two ends of the
authentic molecule does not by itself allow any conclusion about the
parallel or antiparallel orientation of the two subunits. However, the
efficient dimerization of the recombinant H2 and T1 fragments suggests
that these domains are oriented in parallel in the authentic protein.
In addition, in the case of the N-terminal deletions, a kink ~37 nm
from the C-terminal end is identically placed to that seen in the
authentic protein. Taken together, these data clearly indicate that the
two subunits within the authentic CLIP-170 molecule are oriented in a
parallel, unstaggered fashion. Structural analysis of kinesin, a motor
protein, has also revealed a polar molecule with a distinct tripartite
structure consisting of an N-terminal microtubule-binding motor domain,
a central rod domain harboring a kink (32-34), and a C-terminal end
domain most likely interacting with membranes (35). This domain
organization is consistent with the function of motor proteins or CLIPs
of linking cargo molecules or organelles to microtubules.
The recombinant N-terminal domains of CLIP-170 purified after
expression in bacteria appear to be elongated based on biophysical measurements, but they did not reveal a distinct particle morphology by
EM analysis despite the presence of
30 heptad repeats in these truncation constructs. This may indicate that the N-terminal
30 heptad repeats are lacking a coiled-coil "trigger" sequence which, in turn, is absolutely necessary for stable
-helical coiled-coil formation (36, 37). Hence, the dimerization observed for the H2 and H3
fragments by physical measurements may occur by a different mechanism,
potentially yielding only short, out-of-register coiled-coil segments
that are not stable enough to withstand the mechanical shear and stress
occurring during specimen preparation (i.e. spraying, adsorption, and dehydration) for EM analysis. In contrast, fragments T5
and T6 examined by EM appeared consistent with the authentic protein
and indeed contain a coiled-coil trigger sequence identified within the
central rod domain of CLIP-170 (37).
Authentic CLIP-170 analyzed by EM frequently exhibited globular domains
at both ends, whereas the recombinant N-terminal domain (H1) purified
after expression in bacteria appears to be elongated based on
biophysical measurements. A relatively unfolded structure for this
domain may account for its lack of structural stability by EM analysis,
leading to a globular appearance. It is unlikely that this domain was
denatured in our purified proteins, since they can still bind to
microtubules, and we have shown that purified H2 behaves like authentic
CLIP-170 in promoting microtubule assembly and binding preferentially
to polymerizing microtubule ends (8). H2 thus appears to be a good
model protein for the study of the microtubule binding properties of
CLIP-170, and comparison of purified monomeric and dimeric head domains
of CLIP-170 will be useful in future studies of the effect of
dimerization on its interaction with microtubules. Thus, the
microtubule-binding domain of CLIP-170 may be an elongated structure,
although we cannot exclude the possibility that the actual
microtubule-binding moiety of CLIP-170 is indeed folded into a small
globular domain and that it is the presence of an "extended neck"
that gives rise to the predicted elongated form of H1 based on
biophysical measurements. In contrast, the microtubule-binding domain
of kinesin is globular (33, 34), and the microtubule-binding domain of
dynein has also been shown to consist of a globular structure, although
found at the tip of an elongated stalk (38). On the other hand, the microtubule-binding repeat region of tau also appears to be rather elongated (39); this elongated structure may therefore be a characteristic of MBPs, as opposed to motor proteins that display cyclic binding to microtubules during translocation.
We observed two kinks in the rod domain of CLIP-170, each ~37 nm from
the corresponding end. These kinks may add mechanical flexibility to
the long, relatively stiff rod domain which, in turn, may be of
functional significance, for example, to optimize sterically the
binding of CLIP-170 to microtubules and/or vesicles. The rod domain of
kinesin, which appears to be less stable than that of CLIP-170 based on
its
-helical content, contains one kink which might be involved in
regulating kinesin activity by folding back of the C-terminal end
domain onto the N-terminal half of its rod domain (40, 41). Similarly,
myosin can undergo a phosphorylation-induced conformational transition
that regulates filament assembly (42-44). The kinks in the rod domain
of CLIP-170 might similarly regulate the function of this protein as a
microtubule-organelle linker (see below). In this respect, it is
interesting that alternatively spliced isoforms of CLIP-170 exist; a
human isoform with a 35-amino acid insert in the rod domain has been
termed restin (29), and both these isoforms, as well as two others,
have been identified in chicken and human (12, 45). The isoforms are
coexpressed in several tissues, but there are tissue-specific
differences in their expression levels (12, 45). We found that the
protein purified from human placenta did not react with an antibody
raised against amino acids 619-638 of HeLa CLIP-170, a sequence also present in restin and other identified isoforms (12, 45), suggesting
that this represents a further isoform that is the form predominantly
expressed in human placenta. Unlike the identified alternatively
spliced inserts, which are completely conserved between human and
chicken (12, 45), this region is not as well conserved between the two
species (45% identity over 20 amino acids).
Our results suggest that the H1 monomer saturates the microtubule at
two tubulin heterodimers, whereas the H2 dimer saturates it at four
tubulin heterodimers. This would be consistent with binding of one
CLIP-170 head domain to two tubulin heterodimers and independent and
equivalent binding of each head domain in the CLIP-170 dimer. In
contrast, the molar stoichiometry we obtained for the binding of
authentic CLIP-170 to microtubules is much lower. It is possible that
we did not in fact achieve saturation of the microtubules in this
experiment; the large amount of protein required for this experiment
made it impractical to use more. However, it is conceivable that the
~120-nm-long rod domain of the authentic protein causes problems of
steric hindrance. As proposed above, this steric hindrance could be
reduced by introducing kinks into the long, relatively stiff rod
domain, thereby providing a mechanism, in addition to
phosphorylation (19), to regulate (or optimize) the interaction of
CLIP-170 with microtubules. We indeed have evidence that CLIP-170 and
MAP2, both elongated proteins, interfere with the binding of each other
to microtubules, although they do not compete for the same site on
tubulin,2 and heat-stable
MAPs also inhibit binding of endocytotic organelles to microtubules
mediated by CLIP-170 (46). Therefore, steric effects rather than number
of binding sites may limit the binding of large proteins to
microtubules. Consistent with this, the stoichiometry of binding of
several large, asymmetric MAPs, MAP2, MAP1A, and XMAP, has been
measured as 8-9:1, 13-15:1, and 16:1, respectively (47, 48), whereas
that for the lower molecular weight, more globular tau is 2:1 (39),
although MAP2 and tau contain homologous microtubule-binding domains.
The microtubule-binding motifs in the N-terminal domain of CLIP-170 are
also found in a number of other proteins (for summary see Ref. 6), of
which the best characterized is dp150glued, a subunit of the
dynactin complex. The homology is in the N-terminal domain of
dp150glued, which extends from the dynactin complex and appears
to be globular (49). We found the N terminus of CLIP-170 to be rather
elongated according to biophysical measurements, although by EM a pair
of small globular heads was often detected at either end of the
molecule. This difference might be due to the different techniques used to prepare the proteins for EM or might be caused by the presence of
p24 or p27 bound to this domain of dp150glued, but one
difference at the level of the primary structure is the presence of two
copies of the microtubule-binding motif in CLIP-170 compared with only
one in dp150glued. One of the repeats is sufficient to allow
binding of CLIP-170 to microtubules (10), and the dp150glued
polypeptide can bind to microtubules in vitro and in
vivo (50). However, since each of the repeats in CLIP-170 is alone
able to mediate microtubule binding (10, 21), an elongated structure for the authentic CLIP-170 head domain may be necessary to allow both
these sequences to function in interacting with the elongated tubulin
polymer. Interaction of each of these motifs with one subunit of the
polymer would also be consistent with the stoichiometry of microtubule
binding measured for the H1 and H2 proteins.
From the analysis reported here, we conclude that CLIP-170 is an
elongated molecule formed by parallel homodimerization via a
coiled-coil structure. This separates the microtubule-binding domain
from the opposite end, which interacts with other organelles (11). This
head-to-tail domain organization has also been noted for the
microtubule- and actin-based motor proteins (51) and appears to be a
common mechanism for organization of proteins that link an organelle to
the cytoskeleton. The more elongated structure of the
microtubule-binding domain of CLIP-170 compared with kinesin would be
consistent with a microtubule-stabilizing function of CLIP-170, which
could have the cellular role of allowing transient interactions with
organelles to lead to polarization and stabilization of the cytoskeleton.
 |
ACKNOWLEDGEMENTS |
We thank B. Schwendimann for performing the
amino acid analysis of the R fragment. We are grateful to the Lausanne
abattoir for provision of pig brains and to the staff of the Maternity Hospital, Hôpital Université de Genève, for help in
obtaining placentas. We also thank the NCI, National Institutes of
Health (Bethesda), for gifts of paclitaxel.
 |
FOOTNOTES |
*
This work was supported by the Swiss National Science
Foundation (to T. E. K., J. E. R., F. G. v. d. G., and U. A.),
the Canton de Genève (to T. E. K.), the M. E. Müller
Foundation of Switzerland (to U. A), and the Canton Basel-Stadt (to
M. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
b
Present address: Artemis Pharmaceuticals GmbH,
Tübingen, Germany.
c
These authors contributed equally to this work.
d
Present address: Dept. of Cell Biology, Yale University
School of Medicine, New Haven, CT.
e
Present address and to whom correspondence should be
addressed: Dept. of Mental Health, University of Aberdeen Medical
School, Foresterhill, Aberdeen, AB25 2ZD, Scotland. Tel.: 0044 1224 273101; Fax: 0044 1224 849191; E-mail: j.rickard@abdn.ac.uk.
f
Present address: Dept. of Experimental Medicine, University
of Genova, Genova, Italy.
i
Deceased.
2
G. S. Diamantopoulos, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
MBP, microtubule-binding protein;
CLIP, cytoplasmic linker protein;
mAb, monoclonal antibody;
MAP, microtubule-associated protein;
PAGE, polyacrylamide gel electrophoresis;
PCR, polymerase chain reaction;
PIPES, 1,4-piperazinediethanesulfonic acid.
 |
REFERENCES |
| 1.
|
Kirschner, M.,
and Mitchison, T.
(1986)
Cell
45,
329-342[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Rickard, J. E.,
and Kreis, T. E.
(1996)
Trends Cell Biol.
6,
178-183
[CrossRef][Medline]
[Order article via Infotrieve] |
| 3.
|
Goodson, H. V.,
Valetti, C.,
and Kreis, T. E.
(1997)
Curr. Opin. Cell Biol.
9,
18-28[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Schroer, T. A.,
Bingham, J. B.,
and Gill, S. R.
(1996)
Trends Cell Biol.
6,
212-215
|
| 5.
|
Vallee, R. B.,
and Sheetz, M. P.
(1996)
Science
271,
1539-1544[Abstract]
|
| 6.
|
Rickard, J. E.
(1999)
in
Guidebook to the Cytoskeletal and Motor Proteins
(Kreis, T. E.
, and Vale, R. D., eds), 2nd Ed.
, Oxford University Press, Oxford
|
| 7.
|
Rickard, J. E.,
and Kreis, T. E.
(1990)
J. Cell Biol.
110,
1623-1633[Abstract/Free Full Text]
|
| 8.
|
Diamantopoulos, G. S.,
Perez, F.,
Goodson, H. V.,
Batelier, G.,
Melki, R.,
Kreis, T. E.,
and Rickard, J. E.
(1999)
J. Cell Biol.
144,
99-112[Abstract/Free Full Text]
|
| 9.
|
Perez, F.,
Diamantopoulos, G. S.,
Stalder, R.,
and Kreis, T. E.
(1999)
Cell
96,
517-527[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Pierre, P.,
Scheel, J.,
Rickard, J. E.,
and Kreis, T. E.
(1992)
Cell
70,
887-900[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Dujardin, D.,
Wacker, U. I.,
Moreau, A.,
Schroer, T. A.,
Rickard, J. E.,
and De Mey, J. R.
(1998)
J. Cell Biol.
141,
849-862[Abstract/Free Full Text]
|
| 12.
|
Griparic, L.,
Volosky, J. M.,
and Keller, T. C. S., III
(1998)
Gene (Amst.)
206,
195-208[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Lantz, V. A.,
and Miller, K. G.
(1998)
J. Cell Biol.
140,
897-910[Abstract/Free Full Text]
|
| 14.
|
Holzbaur, E. L. F.,
Hammarback, J. A.,
Paschal, B. M.,
Kravit, N. G.,
Pfister, K. K.,
and Vallee, R. B.
(1991)
Nature
351,
579-583[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Swaroop, A.,
Swaroop, M.,
and Garen, A.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
6501-6505[Abstract/Free Full Text]
|
| 16.
|
Trueheart, J.,
Boeke, J. D.,
and Fink, G.
(1987)
Mol. Cell. Biol.
7,
2316-2328[Abstract/Free Full Text]
|
| 17.
|
Tian, G.,
Huang, Y.,
Rommelaere, H.,
Vandekerckhove, J.,
Ampe, C.,
and Cowan, N. J.
(1996)
Cell
86,
287-296[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Tian, G.,
Lewis, S. A.,
Feierbach, B.,
Stearns, T.,
Rommelaere, H.,
Ampe, C.,
and Cowan, N. J.
(1997)
J. Cell Biol.
138,
821-832[Abstract/Free Full Text]
|
| 19.
|
Rickard, J. E.,
and Kreis, T. E.
(1991)
J. Biol. Chem.
266,
17597-17605[Abstract/Free Full Text]
|
| 20.
|
Diamantopoulos, G. S.,
Scheel, J.,
Kreis, T. E.,
and Rickard, J. E.
(1998)
Methods Enzymol.
298,
197-206[Medline]
[Order article via Infotrieve]
|
| 21.
|
Pierre, P.,
Pepperkok, R.,
and Kreis, T. E.
(1994)
J. Cell Sci.
107,
1909-1920[Abstract]
|
| 22.
|
Bruch, M. D.,
Dhingra, M. M.,
and Gierach, L. M.
(1991)
Proteins
10,
130-139[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Provencher, S. W.,
and Glöckner, J.
(1981)
Biochemistry
20,
33-37[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Bloom, G. S.,
Wagner, M. C.,
Pfister, K. K.,
and Brady, S. T.
(1988)
Biochemistry
27,
3409-3416[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Fowler, W. E.,
and Aebi, U.
(1983)
J. Ultrastruct. Res.
83,
319-334[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Häner, M.,
Bremer, A.,
and Aebi, U.
(1997)
in
Cell Biology: A Laboratory Handbook
(Celis, J. E., ed)
, pp. 292-298, Academic Press, San Diego
|
| 28.
|
Müller, S. A.,
Goldie, K. N.,
Bürki, R.,
Häring, R.,
and Engel, A.
(1992)
Ultramicroscopy
46,
317-334[CrossRef]
|
| 29.
|
Bilbe, G.,
Delabie, J.,
Brüggen, J.,
Richener, H.,
Asselbergs, F. A. M.,
Cerletti, N.,
Sorg, C.,
Odink, K.,
Tarcsay, L.,
Wiesendanger, W.,
DeWolf-Peeters, C.,
and Shipman, R.
(1992)
EMBO J.
11,
2103-2113[Medline]
[Order article via Infotrieve]
|
| 30.
|
Bourne, H. R.
(1991)
Nature
351,
188-190[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Mandelkow, E.-M.,
and Mandelkow, E.
(1993)
in
Guidebook to the Cytoskeletal and Motor Proteins
(Kreis, T.
, and Vale, R., eds), 1st Ed.
, pp. 127-130, Oxford University Press, Oxford
|
| 32.
|
Amos, L.
(1987)
J. Cell Sci.
87,
105-111[Abstract]
|
| 33.
|
Hirokawa, N.,
Pfister, K. K.,
Yorifuji, H.,
Wagner, M. C.,
Brady, S. T.,
and Bloom, G. S.
(1989)
Cell
56,
867-878[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Scholey, J. M.,
Heuser, J.,
Yang, J. T.,
and Goldstein, L. S. B.
(1989)
Nature
338,
355-357[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Skoufias, D. A.,
Cole, D. G.,
Wedaman, K. P.,
and Scholey, J. M.
(1994)
J. Biol. Chem.
269,
1477-1485[Abstract/Free Full Text]
|
| 36.
|
Steinmetz, M. O.,
Stock, A.,
Schulthess, T.,
Landwehr, R.,
Lustig, A.,
Faix, J.,
Gerisch, G.,
Aebi, U.,
and Kammerer, R. A.
(1998)
EMBO J.
17,
1883-1891[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Kammerer, R. A.,
Schultess, T.,
Landwehr, R.,
Lustig, A.,
Aebi, U.,
and Steinmetz, M. O.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13419-13424[Abstract/Free Full Text]
|
| 38.
|
Gee, M. A.,
Heuser, J. E.,
and Vallee, R. B.
(1997)
Nature
390,
636-639[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Wille, H.,
Drewes, G.,
Biernat, J.,
Mandelkow, E.-M.,
and Mandelkow, E.
(1992)
J. Cell Biol.
118,
573-584[Abstract/Free Full Text]
|
| 40.
|
Hisanaga, S.,
Murofushi, H.,
Okuhara, K.,
Sato, R.,
Masuda, Y.,
Sakai, H.,
and Hirokawa, N.
(1989)
Cell Motil. Cytoskel.
12,
264-272[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Hackney, D. D.,
Levitt, J. D.,
and Suhan, J.
(1992)
J. Biol. Chem.
267,
8696-8701[Abstract/Free Full Text]
|
| 42.
|
Suzuki, H.,
Kamata, T.,
Onishi, H.,
and Watanabe, S.
(1982)
J. Biochem. (Tokyo)
91,
1699-1705[Abstract/Free Full Text]
|
| 43.
|
Trybus, K. M.,
Huiatt, T. W.,
and Lowey, S.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
6151-6155[Abstract/Free Full Text]
|
| 44.
|
Craig, R.,
Smith, R.,
and Kendrick-Jones, J.
(1983)
Nature
302,
436-439[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Griparic, L.,
and Keller, T. C. S., III
(1998)
Biochim. Biophy. Acta
1405,
35-46[Medline]
[Order article via Infotrieve]
|
| 46.
|
Scheel, J.,
and Kreis, T. E.
(1991)
J. Biol. Chem.
266,
18141-18148[Abstract/Free Full Text]
|
| 47.
|
Pedrotti, B.,
and Islam, K.
(1994)
Biochemistry
33,
12463-12470[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Gard, D. W.,
and Kirschner, M. W.
(1987)
J. Cell Biol.
105,
2203-2215[Abstract/Free Full Text]
|
| 49.
|
Schafer, D. A.,
Gill, S. R.,
Cooper, J. A.,
Heuser, J. E.,
and Schroer, T. A.
(1994)
J. Cell Biol.
126,
403-412[Abstract/Free Full Text]
|
| 50.
|
Waterman-Storer, C. M.,
Karki, S.,
and Holzbaur, E. L.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
1634-1638[Abstract/Free Full Text]
|
| 51.
|
Schliwa, M.
(1989)
Cell
56,
719-720[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.